Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | TTK | P33981 | 3/20 | 0.41 |
| ▸ | QPCT | Q16769 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 4/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.38 |
| ▸ | WNT1 | P04628 | 2/20 | 0.38 |
| ▸ | LDLR | P01130 | 1/20 | 0.38 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7124221 | 0.74 | IDO1 (0.48) | IDO1HPGDSTTKGSK3BDYRK1A | |
| SCHEMBL5489159 | 0.74 | RAF1 (0.54) | ABCG2BRAF | |
| SCHEMBL7127463 | 0.74 | IDO1 (0.43) | IDO1RIPK2HPGDSHTR2CTTK | |
| SCHEMBL20356686 | 0.73 | EGFR (0.61) | ABCB1ABCG2TNFEGFR | |
| SCHEMBL31098967 | 0.73 | ABCG2 (0.64) | ABCB1ABCG2TNFEGFRDYRK1A | |
| SCHEMBL7127641 | 0.72 | AHR (0.58) | TNFEGFR | |
| SCHEMBL1921849 | 0.71 | ABCG2 (0.53) | ABCG2EGFRDYRK1A | |
| SCHEMBL26789989 | 0.71 | TNF (0.64) | ABCB1ABCG2TNFEGFR | |
| SCHEMBL4933191 | 0.71 | TNF (0.64) | ABCG2TNFEGFR | |
| SCHEMBL7117333 | 0.71 | ABL1 (0.54) | IDO1TNFEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176454-A1 | N-coating heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
| WO-2001087845-A2 | N-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS 5-HT ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176454-A1 | N-coating heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 | IDO1 1301/4885RIPK2 3457/4885HPGDS 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.